Methoxyluteolin Inhibits Neuropeptide-stimulated Proinflammatory Mediator Release via mTOR Activation from Human Mast Cells

Journal of Pharmacology and Experimental Therapeutics

Volumn 361, Issue 3, 2017, Pages 462-471

  Patel, Arti B ^a,b   Theoharides, Theoharis C ^a  

^a TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b TUFTS UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FLAVONOID; INTERLEUKIN 8; LUTEOLIN; MAMMALIAN TARGET OF RAPAMYCIN; MAMMALIAN TARGET OF RAPAMYCIN COMPLEX 1; MAMMALIAN TARGET OF RAPAMYCIN COMPLEX 2; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; METHOXYLUTEOLIN; NEUROTENSIN; RAPAMYCIN; SERINE; SUBSTANCE P; THREONINE; TORIN 1; TUMOR NECROSIS FACTOR; UNCLASSIFIED DRUG; VASCULOTROPIN; 5,7,3',4'-TETRAMETHYLLUTEOLIN; AUTACOID; MTOR PROTEIN, HUMAN; NEUROPEPTIDE; TARGET OF RAPAMYCIN KINASE;

ARTICLE; CONTROLLED STUDY; CYTOKINE RELEASE; GENE EXPRESSION; HUMAN; HUMAN CELL; INFLAMMATION; MAST CELL; MEDIATOR RELEASE; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; ANTAGONISTS AND INHIBITORS; CELL SURVIVAL; CHEMISTRY; DOSE RESPONSE; DRUG EFFECTS; METABOLISM; PHYSIOLOGY; SECRETION (PROCESS); TUMOR CELL CULTURE;

CELL SURVIVAL; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; INFLAMMATION MEDIATORS; LUTEOLIN; MAST CELLS; NEUROPEPTIDES; TOR SERINE-THREONINE KINASES; TUMOR CELLS, CULTURED;

EID: 85019849868     PISSN: 00223565     EISSN: 15210103     Source Type: Journal    
DOI: 10.1124/jpet.117.240564     Document Type: Article

References (88)

1. Alysandratos KD, Asadi S, Angelidou A, Zhang B, Sismanopoulos N, Yang H, Critchfield A, and Theoharides TC (2012) Neurotensin and CRH interactions augment human mast cell activation. PLoS One 7:e48934.
2. Angelidou A, Francis K, Vasiadi M, Alysandratos K-D, Zhang B, Theoharides A, Lykouras L, Sideri K, Kalogeromitros D, and Theoharides TC (2010) Neurotensin is increased in serum of young children with autistic disorder. J Neuroinflammation 7:48.
3. Asadi S, Alysandratos KD, Angelidou A, Miniati A, Sismanopoulos N, Vasiadi M, Zhang B, Kalogeromitros D, and Theoharides TC (2012) Substance P (SP) induces expression of functional corticotropin-releasing hormone receptor-1 (CRHR-1) in human mast cells. J Invest Dermatol 132:324-329.
4. Beck LA (2005) The efficacy and safety of tacrolimus ointment: a clinical review. J Am Acad Dermatol 53 (Suppl 2):S165-S170.
5. Blatt K, Herrmann H, Mirkina I, Hadzijusufovic E, Peter B, Strommer S, Hoermann G, Mayerhofer M, Hoetzenecker K, Klepetko W, et al. (2012) The PI3-kinase/mTORtargeting drug NVP-BEZ235 inhibits growth and IgE-dependent activation of human mast cells and basophils. PLoS One 7:e29925.
6. Caltagirone C, Cisari C, Schievano C, Di Paola R, Cordaro M, Bruschetta G, Esposito E, and Cuzzocrea S; Stroke Study Group (2016) Co-ultramicronized palmitoylethanolamide/luteolin in the treatment of cerebral ischemia: from rodent to man. Transl Stroke Res 7:54-69.
7. Caraffa A, Spinas E, Kritas SK, Lessiani G, Ronconi G, Saggini A, Antinolfi P, Pizzicannella J, Toniato E, Theoharides TC, et al. (2016) Endocrinology of the skin: intradermal neuroimmune network, a new frontier. J Biol Regul Homeost Agents 30:339-343.
8. Carraway R and Leeman SE (1973) The isolation of a new hypotensive peptide, neurotensin, from bovine hypothalami. J Biol Chem 248:6854-6861.
9. Chang MM and Leeman SE (1970) Isolation of a sialogogic peptide from bovine hypothalamic tissue and its characterization as substance P. J Biol Chem 245: 4784-4790.
10. Church MK, el-Lati S, and Caulfield JP (1991) Neuropeptide-induced secretion from human skin mast cells. Int Arch Allergy Appl Immunol 94:310-318.
11. Cochrane DE, Carraway RE, Harrington K, Laudano M, Rawlings S, and Feldberg RS (2011) HMC-1 human mast cells synthesize neurotensin (NT) precursor, secrete bioactive NT-like peptide(s) and express NT receptor NTS1. Inflamm Res 60:1139-1151.
12. Dan HC, Cooper MJ, Cogswell PC, Duncan JA, Ting JP, and Baldwin AS (2008) Aktdependent regulation of NF-kappaB is controlled by mTOR and Raptor in association with IKK. Genes Dev 22:1490-1500.
13. Dibble CC and Cantley LC (2015) Regulation of mTORC1 by PI3K signaling. Trends Cell Biol 25:545-555.
14. Donelan J, Boucher W, Papadopoulou N, Lytinas M, Papaliodis D, Dobner P, and Theoharides TC (2006) Corticotropin-releasing hormone induces skin vascular permeability through a neurotensin-dependent process. Proc Natl Acad Sci USA 103:7759-7764.
15. Dong H, Zhang W, Zeng X, Hu G, Zhang H, He S, and Zhang S (2014) Histamine induces upregulated expression of histamine receptors and increases release of inflammatory mediators from microglia. Mol Neurobiol 49:1487-1500.
16. Esposito P, Chandler N, Kandere K, Basu S, Jacobson S, Connolly R, Tutor D, and Theoharides TC (2002) Corticotropin-releasing hormone and brain mast cells regulate blood-brain-barrier permeability induced by acute stress. J Pharmacol Exp Ther 303:1061-1066.
17. Finn DF and Walsh JJ (2013) Twenty-first century mast cell stabilizers. Br J Pharmacol 170:23-37.
18. Furumoto Y, Brooks S, Olivera A, Takagi Y, Miyagishi M, Taira K, Casellas R, Beaven MA, Gilfillan AM, and Rivera J (2006) Cutting edge: lentiviral short hairpin RNA silencing of PTEN in human mast cells reveals constitutive signals that promote cytokine secretion and cell survival. J Immunol 176:5167-5171.
19. Furumoto Y, Charles N, Olivera A, Leung WH, Dillahunt S, Sargent JL, Tinsley K, Odom S, Scott E, Wilson TM, et al (2011) PTEN deficiency in mast cells causes a mastocytosis-like proliferative disease that heightens allergic responses and vascular permeability. Blood 118:5466-5475.
20. Gabillot-Carré M, Lepelletier Y, Humbert M, de Sepuvelda P, Hamouda NB, Zappulla JP, Liblau R, Ribadeau-Dumas A, Machavoine F, Letard S, et al. (2006) Rapamycin inhibits growth and survival of D816V-mutated c-kit mast cells. Blood 108:1065-1072.
21. Galli SJ, Grimbaldeston M, and Tsai M (2008) Immunomodulatory mast cells: negative, as well as positive, regulators of immunity. Nat Rev Immunol 8:478-486.
22. Galli SJ and Tsai M (2012) IgE and mast cells in allergic disease. Nat Med 18: 693-704.
23. Gilfillan AM and Rivera J (2009) The tyrosine kinase network regulating mast cell activation. Immunol Rev 228:149-169.
24. Gotlib J, Kluin-Nelemans HC, George TI, Akin C, Sotlar K, Hermine O, Awan FT, Hexner E, Mauro MJ, Sternberg DW, et al (2016) Efficacy and safety of midostaurin in advanced systemic mastocytosis. N Engl J Med 374:2530-2541.
25. Guhl S, Babina M, Neou A, Zuberbier T, and Artuc M (2010) Mast cell lines HMC-1 and LAD2 in comparison with mature human skin mast cells-drastically reduced levels of tryptase and chymase in mast cell lines. Exp Dermatol 19:845-847.
26. Heinrich MC, Griffith DJ, Druker BJ, Wait CL, Ott KA, and Zigler AJ (2000) Inhibition of c-kit receptor tyrosine kinase activity by STI 571, a selective tyrosine kinase inhibitor. Blood 96:925-932.
27. Holowka D, Calloway N, Cohen R, Gadi D, Lee J, Smith NL, and Baird B (2012) Roles for ca(2+) mobilization and its regulation in mast cell functions. Front Immunol 3: 104.
28. Kempuraj D, Madhappan B, Christodoulou S, Boucher W, Cao J, Papadopoulou N, Cetrulo CL, and Theoharides TC (2005) Flavonols inhibit proinflammatory mediator release, intracellular calcium ion levels and protein kinase C theta phosphorylation in human mast cells. Br J Pharmacol 145:934-944.
29. Kim MS, Kuehn HS, Metcalfe DD, and Gilfillan AM (2008a) Activation and function of the mTORC1 pathway in mast cells. J Immunol 180:4586-4595.
30. Kim MS, Rådinger M, and Gilfillan AM (2008b) The multiple roles of phosphoinositide 3-kinase in mast cell biology. Trends Immunol 29:493-501.
31. Kimata M, Shichijo M, Miura T, Serizawa I, Inagaki N, and Nagai H (2000) Effects of luteolin, quercetin and baicalein on immunoglobulin E-mediated mediator release from human cultured mast cells. Clin Exp Allergy 30:501-508.
32. Kirshenbaum AS, Akin C, Wu Y, Rottem M, Goff JP, Beaven MA, Rao VK, and Metcalfe DD (2003) Characterization of novel stem cell factor responsive human mast cell lines LAD 1 and 2 established from a patient with mast cell sarcoma/leukemia; activation following aggregation of FcepsilonRI or FcgammaRI. Leuk Res 27:677-682.
33. Kitamura Y and Ito A (2005) Mast cell-committed progenitors. Proc Natl Acad Sci USA 102:11129-11130.
34. Kuehn HS, Jung MY, Beaven MA, Metcalfe DD, and Gilfillan AM (2011) Prostaglandin E2 activates and utilizes mTORC2 as a central signaling locus for the regulation of mast cell chemotaxis and mediator release. J Biol Chem 286:391-402.
35. Kulka M, Sheen CH, Tancowny BP, Grammer LC, and Schleimer RP (2008) Neuropeptides activate human mast cell degranulation and chemokine production. Immunology 123:398-410.
36. Laplante M and Sabatini DM (2012) mTOR signaling in growth control and disease. Cell 149:274-293.
37. Laplante M and Sabatini DM (2013) Regulation of mTORC1 and its impact on gene expression at a glance. J Cell Sci 126:1713-1719.
38. Lazarus LH, Perrin MH, and Brown MR (1977) Mast cell binding of neurotensin. I. Iodination of neurotensin and characterization of the interaction of neurotensin with mast cell receptor sites. J Biol Chem 252:7174-7179.
39. Mashaghi A, Marmalidou A, Tehrani M, Grace PM, Pothoulakis C, and Dana R (2016) Neuropeptide substance P and the immune response. Cell Mol Life Sci 73: 4249-4264.
40. McNeil BD, Pundir P, Meeker S, Han L, Undem BJ, Kulka M, and Dong X (2015) Identification of a mast-cell-specific receptor crucial for pseudo-allergic drug reactions. Nature 519:237-241.
41. Metcalfe DD and Akin C (2001) Mastocytosis: molecular mechanisms and clinical disease heterogeneity. Leuk Res 25:577-582.
42. Michel G, Kemeny L, Homey B, and Ruzicka T (1996) FK506 in the treatment of inflammatory skin disease: promises and perspectives. Immunol Today 17:106-108.
43. Middleton E, Jr, Kandaswami C, and Theoharides TC (2000) The effects of plant flavonoids on mammalian cells: implications for inflammation, heart disease, and cancer. Pharmacol Rev 52:673-751.
44. Mlcek J, Jurikova T, Skrovankova S, and Sochor J (2016) Quercetin and its antiallergic immune response. Molecules 21:E623.
45. O'Connor TM, O'Connell J, O'Brien DI, Goode T, Bredin CP, and Shanahan F (2004) The role of substance P in inflammatory disease. J Cell Physiol 201:167-180.
46. Oka T, Kalesnikoff J, Starkl P, Tsai M, and Galli SJ (2012) Evidence questioning cromolyn's effectiveness and selectivity as a 'mast cell stabilizer' in mice. Lab Invest 92:1472-1482.
47. Palaska I, Gagari E, and Theoharides TC (2016) The effects of P. gingivalis and E. coli LPS on the expression of proinflammatory mediators in human mast cells and their relevance to periodontal disease. J Biol Regul Homeost Agents 30:655-664.
48. Pang X, Alexacos N, Letourneau R, Seretakis D, Gao W, Boucher W, Cochrane DE, and Theoharides TC (1998) A neurotensin receptor antagonist inhibits acute immobilization stress-induced cardiac mast cell degranulation, a corticotropin-releasing hormone-dependent process. J Pharmacol Exp Ther 287:307-314.
49. Parikh SA, Kantarjian HM, Richie MA, Cortes JE, and Verstovsek S (2010) Experience with everolimus (RAD001), an oral mammalian target of rapamycin inhibitor, in patients with systemic mastocytosis. Leuk Lymphoma 51:269-274.
50. Park JW, Jeon YJ, Lee JC, Ahn SR, Ha SW, Bang SY, Park EK, Yi SA, Lee MG, and Han JW (2012) Destabilization of TNF-α mRNA by rapamycin. Biomol Ther (Seoul) 20:43-49.
51. Patel AB, Tsilioni I, Leeman SE, and Theoharides TC (2016) Neurotensin stimulates sortilin and mTOR in human microglia inhibitable by methoxyluteolin, a potential therapeutic target for autism. Proc Natl Acad Sci USA 113:E7049-E7058.
52. Piliponsky AM, Chen CC, Nishimura T, Metz M, Rios EJ, Dobner PR, Wada E, Wada K, Zacharias S, Mohanasundaram UM, et al (2008) Neurotensin increases mortality and mast cells reduce neurotensin levels in a mouse model of sepsis. Nat Med 14:392-398.
53. Quinlan KL, Song IS, Naik SM, Letran EL, Olerud JE, Bunnett NW, Armstrong CA, Caughman SW, and Ansel JC (1999) VCAM-1 expression on human dermal microvascular endothelial cells is directly and specifically up-regulated by substance P. J Immunol 162:1656-1661.
54. Remröd C, Lonne-Rahm S, and Nordlind K (2007) Study of substance P and its receptor neurokinin-1 in psoriasis and their relation to chronic stress and pruritus. Arch Dermatol Res 299:85-91.
55. Rivera J, Fierro NA, Olivera A, and Suzuki R (2008) New insights on mast cell activation via the high affinity receptor for IgE. Adv Immunol 98:85-120.
56. Rodewald HR, Dessing M, Dvorak AM, and Galli SJ (1996) Identification of a committed precursor for the mast cell lineage. Science 271:818-822.
57. Salamon P, Shoham NG, Gavrieli R, Wolach B, and Mekori YA (2005) Human mast cells release interleukin-8 and induce neutrophil chemotaxis on contact with activated T cells. Allergy 60:1316-1319.
58. Saleiro D and Platanias LC (2015) Intersection of mTOR and STAT signaling in immunity. Trends Immunol 36:21-29.
59. Schmetzer O, Valentin P, Church MK, Maurer M, and Siebenhaar F (2016) Murine and human mast cell progenitors. Eur J Pharmacol 778:2-10.
60. Seok J, Warren HS, Cuenca AG, Mindrinos MN, Baker HV, Xu W, Richards DR, McDonald-Smith GP, Gao H, Hennessy L, et al.; Inflammation and Host Response to Injury, Large Scale Collaborative Research Program (2013) Genomic responses in mouse models poorly mimic human inflammatory diseases. Proc Natl Acad Sci USA 110:3507-3512.
61. Siegel AM, Stone KD, Cruse G, Lawrence MG, Olivera A, Jung MY, Barber JS, Freeman AF, Holland SM, O'Brien M, et al (2013) Diminished allergic disease in patients with STAT3 mutations reveals a role for STAT3 signaling in mast cell degranulation. J Allergy Clin Immunol 132:1388-1396.
62. Skaper SD, Facci L, and Giusti P (2014) Mast cells, glia and neuroinflammation: partners in crime? Immunology 141:314-327.
63. Smrz D, Cruse G, Beaven MA, Kirshenbaum A, Metcalfe DD, and Gilfillan AM (2014) Rictor negatively regulates high-affinity receptors for IgE-induced mast cell degranulation. J Immunol 193:5924-5932.
64. Smrz D, Kim MS, Zhang S, Mock BA, Smrzová S, DuBois W, Simakova O, Maric I, Wilson TM, Metcalfe DD, et al. (2011) mTORC1 and mTORC2 differentially regulate homeostasis of neoplastic and non-neoplastic human mast cells. Blood 118:6803-6813.
65. Sumpter TL, Ho CH, Pleet AR, Tkacheva OA, Shufesky WJ, Rojas-Canales DM, Morelli AE, and Larregina AT (2015) Autocrine hemokinin-1 functions as an endogenous adjuvant for IgE-mediated mast cell inflammatory responses. J Allergy Clin Immunol 135:1019-30.e8.
66. Takayama G, Ohtani M, Minowa A, Matsuda S, and Koyasu S (2013) Class I PI3K-mediated Akt and ERK signals play a critical role in FcϵRI-induced degranulation in mast cells. Int Immunol 25:215-220.
67. Taliou A, Zintzaras E, Lykouras L, and Francis K (2013) An open-label pilot study of a formulation containing the anti-inflammatory flavonoid luteolin and its effects on behavior in children with autism spectrum disorders. Clin Ther 35:592-602.
68. Theoharides TC, Alysandratos KD, Angelidou A, Delivanis DA, Sismanopoulos N, Zhang B, Asadi S, Vasiadi M, Weng Z, Miniati A, et al (2012a) Mast cells and inflammation. Biochim Biophys Acta 1822:21-33.
69. Theoharides TC, Asadi S, and Panagiotidou S (2012b) A case series of a luteolin formulation (NeuroProtek®) in children with autism spectrum disorders. Int J Immunopathol Pharmacol 25:317-323.
70. Theoharides TC and Cochrane DE (2004) Critical role of mast cells in inflammatory diseases and the effect of acute stress. J Neuroimmunol 146:1-12.
71. Theoharides TC, Sieghart W, Greengard P, and Douglas WW (1980) Antiallergic drug cromolyn may inhibit histamine secretion by regulating phosphorylation of a mast cell protein. Science 207:80-82.
72. Theoharides TC, Tsilioni I, Patel AB, and Doyle R (2016) Atopic diseases and inflammation of the brain in the pathogenesis of autism spectrum disorders. Transl Psychiatry 6:e844.
73. Theoharides TC, Valent P, and Akin C (2015) Mast cells, mastocytosis, and related disorders. N Engl J Med 373:163-172.
74. Theoharides TC, Zhang B, Kempuraj D, Tagen M, Vasiadi M, Angelidou A, Alysandratos KD, Kalogeromitros D, Asadi S, Stavrianeas N, et al. (2010) IL-33 augments substance P-induced VEGF secretion from human mast cells and is increased in psoriatic skin. Proc Natl Acad Sci USA 107:4448-4453.
75. Tsilioni I, Dodman N, Petra AI, Taliou A, Francis K, Moon-Fanelli A, Shuster L, and Theoharides TC (2014) Elevated serum neurotensin and CRH levels in children with autistic spectrum disorders and tail-chasing Bull Terriers with a phenotype similar to autism. Transl Psychiatry 4:e466.
76. Tsilioni I, Russell IJ, Stewart JM, Gleason RM, and Theoharides TC (2016) Neuropeptides CRH, SP, HK-1, and inflammatory cytokines IL-6 and TNF are increased in serum of patients with fibromyalgia syndrome, implicating mast cells. J Pharmacol Exp Ther 356:664-672.
77. Vasiadi M, Therianou A, Sideri K, Smyrnioti M, Sismanopoulos N, Delivanis DA, Asadi S, Katsarou-Katsari A, Petrakopoulou T, Theoharides A, et al. (2012) Increased serum CRH levels with decreased skin CRHR-1 gene expression in psoriasis and atopic dermatitis. J Allergy Clin Immunol 129:1410-1413.
78. Vieira Dos Santos R, Magerl M, Martus P, Zuberbier T, Church MK, Escribano L, and Maurer M (2010) Topical sodium cromoglicate relieves allergen- and histamine-induced dermal pruritus. Br J Dermatol 162:674-676.
79. Walle T (2007) Methylation of dietary flavones greatly improves their hepatic metabolic stability and intestinal absorption. Mol Pharm 4:826-832.
80. Weichhart T, Costantino G, Poglitsch M, Rosner M, Zeyda M, Stuhlmeier KM, Kolbe T, Stulnig TM, Hörl WH, Hengstschläger M, et al. (2008) The TSC-mTOR signaling pathway regulates the innate inflammatory response. Immunity 29:565-577.
81. Weng Z, Patel AB, Panagiotidou S, and Theoharides TC (2015) The novel flavone tetramethoxyluteolin is a potent inhibitor of human mast cells. J Allergy Clin Immunol 135:1044-52.e5.
82. Weng Z, Zhang B, Asadi S, Sismanopoulos N, Butcher A, Fu X, Katsarou-Katsari A, Antoniou C, and Theoharides T (2012) Quercetin is more effective than cromolyn in blocking human mast cell cytokine release and inhibits contact dermatitis and photosensitivity in humans. PLoS One 7:e33805.
83. Williamson G and Manach C (2005) Bioavailability and bioefficacy of polyphenols in humans. II. Review of 93 intervention studies. Am J Clin Nutr 81 (Suppl):243S-255S.
84. Willsey AJ and State MW (2015) Autism spectrum disorders: from genes to neurobiology. Curr Opin Neurobiol 30:92-99.
85. Xagorari A, Papapetropoulos A, Mauromatis A, Economou M, Fotsis T, and Roussos C (2001) Luteolin inhibits an endotoxin-stimulated phosphorylation cascade and proinflammatory cytokine production in macrophages. J Pharmacol Exp Ther 296:181-187.
86. Yang Y, Heo P, Kong B, Park JB, Jung YH, Shin J, Jeong C, and Kweon DH (2015) Dynamic light scattering analysis of SNARE-driven membrane fusion and the effects of SNARE-binding flavonoids. Biochem Biophys Res Commun 465:864-870.
87. Zhang B, Asadi S, Weng Z, Sismanopoulos N, and Theoharides TC (2012a) Stimulated human mast cells secrete mitochondrial components that have autocrine and paracrine inflammatory actions. PLoS One 7:e49767.
88. Zhang S, Zeng X, Yang H, Hu G, and He S (2012b) Mast cell tryptase induces microglia activation via protease-activated receptor 2 signaling. Cell Physiol Biochem 29:931-940.